“Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s55. doi:10.25251/skin.5.supp.55.